Thomas Fuchs, the Dean of Artificial Intelligence and Human Health at Mount Sinai in NYC, said AI will be needed to retain the standard of care in the U.S. Artificial intelligence (AI) is helping physicians to diagnose cancer more accurately at much faster rates and at a lower cost than previously possible, according to a scientist working in computational pathology. Dr. Thomas J. Fuchs, the Dean of Artificial Intelligence and Human Health at Mount Sinai in New York City, also works as the chief scientific officer at Paige AI, a company using AI to detect and treat cancer. The latest study from the company tasked 16 pathologists with the review of 610 whole-slide images prepared at multiple institutions globally. They reviewed the slides once without assistance, and then again with assistance from the Pathology Artificial Intelligence Guidance Engine (Paige AI). When Paige AI was used, diagnostic errors reduced by 70%.

Novel artificial intelligence methods have revealed unexpected microscopic abnormalities that can predict cognitive impairment, according to a study led by researchers at Mount Sinai. These findings were published in the journal Acta Neuropathologica Communications this week. "AI represents an entirely new paradigm for studying dementia and will have a transformative effect on research into complex brain diseases, especially Alzheimer's disease," said co-corresponding author John Crary, MD, PhD, Professor of Pathology, Molecular and Cell-Based Medicine, Neuroscience, and Artificial Intelligence and Human Health, at the Icahn School of Medicine at Mount Sinai. He added that, "The deep learning approach was applied to the prediction of cognitive impairment, a challenging problem for which no current human-performed histopathologic diagnostic tool exists." The Mount Sinai team identified and analyzed the underlying architecture and cellular features of two regions in the brain, the medial temporal lobe and frontal cortex.

Use of artificial intelligence (AI) by hospitals is now hitting its stride after a long ramp-up as more systems and facilities sink serious dollars and effort into connected healthcare. Funded in part by a $20 million grant from the National Institute on Aging (NIA), MassAITC's stated mission is to advance in-home connected care as "90% of older Americans would prefer to stay in their homes as they age," but with Alzheimer's presenting daunting challenges. "While at-home health care technologies hold significant promise, they have not been specifically developed for older adults or Alzheimer's patients, caregivers and their clinicians. Further, many current treatment and intervention regimes are limited in terms of their ability to be remotely delivered, managed and adapted to patient needs and caregiver abilities." Adapting to consumers' developing digital health preferences is becoming a prime differentiator for providers.

The Department of Artificial Intelligence and Human Health mission is to lead the artificial intelligence-driven transformation of health care through innovative research, apply that knowledge to treatment in hospital and clinical settings, and provide personalized care for each patient, which will expand Mount Sinai's impact on human health across the Health System and around the world. This effort will include creating a hub-and-satellite model to make new tools and techniques available to all Mount Sinai physicians and building an infrastructure for high-performance computing and data access to improve Mount Sinai's diagnostic and treatment capabilities. The Department of AI and Human Health is also launching a campaign to recruit talented researchers, scientists, physicians, and students in the field. MSDW data goes back to 2003, covering a variety of EMR and ancillary systems at The Mount Sinai Hospital and expanding to Mount Sinai Queens, and in recent years, Mount Sinai Morningside, Mount Sinai West, and Mount Sinai Brooklyn hospitals. The MSDW team offers a list of data services to access custom data sets, custom data marts, and de-identified data.